Who We Are

HMR starts phase 2 trial of new vaccine against the Ebola virus

In September 2015, HMR started dosing in a phase 2 study of a promising new vaccine against the Ebola virus. The current outbreak in West Africa is estimated to have caused more than 10,000 deaths, and although the number of new cases has dropped significantly, the WHO has warned that the disease could break out again at any time. There's no specific treatment or cure for Ebola, so an effective vaccine would be an important step in controlling the spread of disease.

Back to list
National Training AwardsCyber EssentialsDigital XRaidA proud member of UK BioIndustry Associationone nucleus